Business Context and Reporting Period
Company: LeMaitre Vascular, Inc. (LMAT)
Filing Type: Form 8-K (Current Report)
Date of Report: August 1, 2023
Reporting Period: Preliminary results for the quarter ended June 30, 2023.
This filing serves to announce the issuance of a press release containing preliminary financial and operational results. The detailed financial data is contained within Exhibit 99.1 and is not explicitly detailed in the body of this 8-K text.
Key Financial Metrics
The text of this Form 8-K does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being included in the attached press release (Exhibit 99.1) but are not present in the provided filing text.
Material Changes
No specific material changes versus the prior comparable period are detailed in this document. The filing indicates that the Company has issued preliminary results, but the specific variances or trends are not described in the main text.
Guidance, Outlook, and Risks
- Forward-Looking Statements: The filing contains a standard disclaimer regarding forward-looking statements, noting they are based on management's current preliminary expectations and are subject to risks and uncertainties.
- Risk Factors: Investors are directed to the "Risk Factors" section of the Company's most recent Annual Report on Form 10-K and subsequent filings for a detailed list of risks.
- Outlook: No specific guidance or outlook figures are provided in this text; the Company undertakes no obligation to update forward-looking statements.
Investor Verification Checklist
- Review Exhibit 99.1 (the press release) for the actual preliminary revenue, net income, and EPS figures for the quarter ended June 30, 2023.
- Verify the specific operational highlights and segment performance mentioned in the press release.
- Consult the most recent Form 10-K for the full list of risk factors referenced in the disclaimer.
- Confirm whether the preliminary results align with any previously issued guidance.